klow cancer Pink Day GH peptides + KLOW blend

Ferroptosis: A novel anti-tumor action for cisplatin

Ipamorelin + CJC-1295 Stack: Evidence, Mechanism, and Protocol At a glance Drug class / Growth hormone secretagogue (GHRP) + Growth hormone-releasing hormone analogue (GHRH analogue) Ipamorelin receptor target / Ghrelin receptor (GHSR-1a), selective, no cortisol or prolactin spike CJC-1295 receptor target / GHRH receptor (GHRHR) on pituitary somatotrophs Combination mechanism / GHRP + GHRH co-stimulation raises GH pulse amplitude 2-to-10-fold over either agent alone in animal models Typical ipamorelin dose / 100-300 mcg subcutaneous injection, 1-3x daily Typical CJC-1295 (no DAC) dose / 100-300 mcg subcutaneous injection, timed with ipamorelin Typical CJC-1295 with DAC dose / 1,000-2,000 mcg subcutaneous injection, once weekly Primary evidence level / Mechanistic + animal + one Phase II RCT (CJC-1295)

Budget for at least 3 months to assess results, as most peptides require 8-12 weeks for noticeable effects

It also helps to maintain the antioxidant activity of Vitamin C & E